Peptivo review

Peptivo is worth considering only after the seller resolves its package, refund and geographic conflicts in writing. The disclosed injection offer is more concrete than the homepage’s illustrative treatment concepts, but it still lacks a verified complete purchase obligation.

Peptivo presents an online pathway to a free assessment and an independent clinician’s treatment decision. Its homepage links the women’s program to a dedicated GLP-1 offer page, where injectable preparations and ninety-day bundles are advertised. This supports evaluating that particular consumer offer, while leaving the identity of the incorporated operator and actual treating medical practice unresolved.

The broader homepage explicitly describes some treatment routes as illustrative concepts. Its perspectives and portraits are not actual patient reviews or demonstrated outcomes, and a note calls for an applicable verified provider roster in production. These qualifications matter: depicted formats, clinician or school references and testimonial-style presentation cannot establish current product availability, verified credentials or treatment results.

The dedicated offer attributes semaglutide/glycine/B12 and tirzepatide/glycine/B12 injections to Strive Pharmacy. That is the seller’s product and pharmacy attribution, not independent verification of pharmacy licensing or confirmation of the pharmacy assigned to a particular order. Ask for the dispensing pharmacy and treating practice as part of the proposed prescription, rather than relying on the platform’s branding alone.

The advertised process begins with an assessment followed by clinician review. A prescription is not guaranteed, and the public sources do not establish a complete age or BMI checklist, individual exclusions, laboratory requirements or the exact consultation format. Confirm those requirements before assuming that completing the assessment makes the advertised package available to you.

State eligibility is inconsistent across the public material. The offer includes all-fifty-states-and-DC care language, but its expanded FAQ excludes Alaska and Hawaii. The terms restrict service to the fifty United States and exclude territories and international access; that boundary does not resolve the more specific Alaska/Hawaii exclusions or establish DC access. Obtain confirmation for the state where you will actually receive treatment.

The seller advertises ongoing care, delivery, no membership or hidden fees and price stability as treatment progresses. Those are stated program inclusions, not independently measured support quality or a guarantee that every possible service is free. Ask who handles clinical follow-up, how refill review occurs and whether testing, replacement shipments or changes to treatment can add charges.

The free assessment is separate from the financial rules attached to a prescription order. In particular, the terms link submission of prescription intake to a nonrefundability rule. Read the agreement presented at that stage and determine when payment is captured; do not assume that the assessment’s free label creates a later cancellation right.

The women’s GLP-1 page advertises semaglutide/glycine/B12 injections from $3.19 per day and tirzepatide/glycine/B12 injections from $7.06 per day in ninety-day titration or maintenance bundles. These rounded daily minima do not establish a monthly debit or the complete ninety-day charge. The actual bundle total, payment schedule, renewal and supplied amount were not verified, so converting the daily figures into an invoice would overstate what is known.

The terms separately list $179 semaglutide and $279 tirzepatide initial and follow-up packages, describing the initial package as a first month. Those packages include consultation, prescription, medication, shipping and support. The relationship between these figures and the daily ninety-day offer is unresolved. Neither set should be treated as the controlling price for the other, and no standard recurring monthly price is established by combining them.

Before purchasing, request one quote identifying the precise preparation, quantity, bundle duration, full commitment, due-now amount, later payments and any renewal. Confirm whether the quoted offer is an initial package, follow-up package or ninety-day bundle, and which agreement applies. Seasonal promotion wording does not establish that a discount remains valid for a selected purchase or reveal the post-promotion price.

The landing page promotes a broad thirty-day money-back or weight-loss guarantee. The terms describe a substantially narrower refund policy: initial medical disqualification, subject to an exception for misrepresented information, or a billing error. Prescription orders after intake submission and processed subscription charges are generally nonrefundable. Cancellation is described as preventing future charges, which does not explain reimbursement of an unused bundle balance.

Eligible refund claims have a twenty-eight-day written deadline. One instruction allows mail, while the next specifies email only. That procedural conflict and the shorter, limited terms are material differences from a general thirty-day satisfaction promise. Obtain the applicable refund grounds, deadline and submission channel in writing, including treatment and service components, before relying on the marketing guarantee.

The exact cancellation method and cutoff, renewal cadence and settlement of unused prepaid treatment remain unclear. Ask when cancellation must be received to stop the next debit, how confirmation is issued and whether any remaining installment obligation survives stopping care. Included shipping alone does not establish dispatch time, delivery speed or a guaranteed arrival date. These commercial details are part of the cost comparison even when the headline says there are no hidden fees.

The concrete offer reviewed here is compounded semaglutide/glycine/B12 and tirzepatide/glycine/B12 injections. Compounded medicines are not FDA approved, and the ingredient list does not independently establish effectiveness, equivalence to an approved drug or suitability for a particular patient. Other branded-drug, sermorelin and NAD+ packages appear in the terms, but that listing alone does not establish current availability. Confirm the actual prescription, concentration, quantity, storage requirements and pharmacy with the treating team; illustrative homepage formats are not a substitute for that information.